Clinical Trial Update: Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab [Phase 2]

View source ↗

Summary

A Phase 2 trial is investigating adjuvant treatment with donafenib in combination with envafolimab for patients with a high risk of recurrent hepatocellular car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Donafenib (donafenib)
• Envafolimab (envafolimab)

Snippet

Sponsor: Anhui Provincial Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING